Clinical Trial Update: Kosmos Trio and Ejection Fraction Pivotal Study

View source ↗

Summary

Update on the Kosmos Trio ejection fraction pivotal study by EchoNous Inc.; the trial has completed in cardiovascular disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Drugs mentioned

• Kosmos Trio

Snippet

Sponsor: EchoNous Inc. | Conditions: Cardiac Disease | Status: COMPLETED